XENTION LTD ("Xention"), the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, announced today that it had secured £1.4m co-funding from the Technology Strategy Board, the UK’s innovation agency, to progress its novel IKACh channel blockers through pre-clinical development.